Video

Dr. Walker on the Use of Radiation Therapy in Patients With Breast Cancer

Eleanor M. Walker, MD, senior staff physician, division director, Breast Services in the Department of Radiation Oncology, Henry Ford Cancer Institute, discusses the use of radiation therapy in patients with breast cancer.

Eleanor M. Walker, MD, senior staff physician, division director, Breast Services, Department of Radiation Oncology, Henry Ford Cancer Institute, discusses the use of radiation therapy in patients with breast cancer.

One of the areas where clinicians are starting to get a lot of data is in patients who are receiving chemotherapy in addition to radiation, and potentially hormone therapy. Originally, clinicians thought that if patients received a slightly higher dose of radiation, they would experience more skin reactions.

However, clinicians now have data that show that they can treat women who have received, or are going to receive chemotherapy and have the same results. Younger patients are also candidates for radiation therapy. Women under the age of 50 can benefit from radiation therapy without showing any more side effects down the road, says Walker.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD